Topics
CNS Tumors | Treatment | Targeted therapy | Ramucirumab
Home > Publications > Topics > CNS Tumors > Treatment > Targeted therapy > Ramucirumab
Pilbeam KL, Pradhan K, Croop J,
Minard CG, Liu X, Voss SD, Isikwei E, Berg SL, Reid JM, Fox E,
Weigel BJ.
A
phase 1 trial utilizing a pharmacokinetic endpoint to determine
the optimal dose of ramucirumab in children and adolescents with
relapsed or refractory solid tumors, including central nervous
system tumors.
Pediatr
Blood Cancer.
2024 Jan 8:e30817. doi:
10.1002/pbc.30817. PMID:
38189770. Interventional study˰ ˍ